List of Excipients in Branded Drug SOTALOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ALTATHERA Pharmaceuticals LLC	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	69724-112	ACETIC ACID
ALTATHERA Pharmaceuticals LLC	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	69724-112	SODIUM HYDROXIDE
ALTATHERA Pharmaceuticals LLC	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	69724-112	WATER

Generic Drugs Containing SOTALOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	sotalol hydrochloride	0093-1061	FD&C BLUE NO. 2
Teva Pharmaceuticals USA Inc	sotalol hydrochloride	0093-1061	INDIGOTINDISULFONATE SODIUM
Teva Pharmaceuticals USA Inc	sotalol hydrochloride	0093-1061	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	sotalol hydrochloride	0093-1061	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	sotalol hydrochloride	0093-1061	POVIDONE K30
Teva Pharmaceuticals USA Inc	sotalol hydrochloride	0093-1061	STARCH, CORN

What are the Most Frequently-Used Excipients in SOTALOL HYDROCHLORIDE?

# Of NDCs	Excipient
4	ANHYDROUS LACTOSE
36	CELLULOSE, MICROCRYSTALLINE
2	FD&C BLUE NO. 1
8	FD&C BLUE NO. 2
3	FD&C BLUE NO. 2 ALUMINUM LAKE
11	FD&C BLUE NO. 2--ALUMINUM LAKE

Sotalol Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Sotalol hydrochloride is a mature, genericized antiarrhythmic with limited active-ingredient patent protection and a concentrated formulation opportunity. The strongest commercial positions are differentiated oral liquids, pediatric and geriatric dosage forms, low-cost tablets, and manufacturing platforms that manage dose uniformity, dissolution, taste, and renal-dose flexibility.

Sotalol hydrochloride is marketed primarily as immediate-release tablets and oral solution. The active ingredient is used for atrial fibrillation, atrial flutter, and ventricular arrhythmias. Its safety profile creates a higher regulatory burden than its simple tablet formulation suggests: initiation or reinitiation generally requires cardiac monitoring because sotalol can prolong the QT interval and cause torsades de pointes. Renal function materially affects dosing because the drug is eliminated largely through the kidneys.[1]

What dosage forms and excipient systems are used for sotalol hydrochloride?

The principal commercial dosage forms are immediate-release tablets and a 5 mg/mL oral solution.

Dosage form	Typical strengths or concentration	Primary excipient requirements	Commercial role
Immediate-release tablet	80, 120, 160, 240 mg	Diluent, binder, disintegrant, lubricant, flow aid	Lowest-cost generic platform
Oral solution	5 mg/mL	Buffer, preservative, sweetener, flavor, viscosity and stability agents	Pediatric, geriatric, dysphagia, and dose-flexibility market
Extemporaneous liquid	Variable	Vehicle, suspending or solubilizing system, preservative	Compounding and institutional use
Modified-release product	Not a mainstream FDA-approved reference presentation	Release-controlling polymer, coating, or multiparticulate system	Higher development risk and limited clinical rationale

Reference tablet formulations have used lactose, microcrystalline cellulose, starch, and magnesium stearate. Generic manufacturers may use different combinations, including crospovidone, povidone, colloidal silicon dioxide, and alternative grades of cellulose or starch.[2-5]

The oral solution opportunity is more technically differentiated. A commercial liquid must maintain chemical stability, microbial control, acceptable taste, dose accuracy, and compatibility with dosing syringes. The formulation must also accommodate renal dose adjustment, which can create demand for flexible volumetric dosing.

How does sotalol hydrochloride’s chemistry affect excipient selection?

Sotalol hydrochloride is a highly water-soluble salt with high oral bioavailability. The FDA label reports oral bioavailability of approximately 90% to 100%, with food reducing absorption by approximately 20%.[1] These properties favor a conventional immediate-release formulation rather than a solubility-enhancing technology.

The principal formulation variables are:

1. Blend uniformity at relatively low tablet weights.
2. Rapid and reproducible disintegration.
3. Control of lubricant impact on dissolution.
4. Chemical stability in aqueous formulations.
5. Palatability for liquid products.
6. Compatibility with renal-dose titration.

Solubility and dissolution

Because sotalol hydrochloride is readily soluble, the commercial value of a tablet formulation is unlikely to come from nanocrystals, amorphous solid dispersions, lipid systems, or complex solubilizers. Such technologies could increase manufacturing cost without solving a major product limitation.

A conventional direct-compression or wet-granulation platform is more commercially rational. Microcrystalline cellulose can support compactibility, while crospovidone or sodium starch glycolate can accelerate disintegration. Excessive magnesium stearate may slow wetting and dissolution, making lubricant concentration and mixing time relevant process controls.

Dose uniformity

Sotalol tablets are available in strengths up to 240 mg, but patients may receive individualized regimens based on renal function and QT response. A platform with strong content uniformity across 80 mg, 120 mg, 160 mg, and 240 mg strengths can reduce manufacturing complexity.

The most efficient architecture is often a common excipient system with strength-specific active loading and scalable tooling. Tablet scoring can support dose splitting, but any split-tablet claim requires appropriate scoring design and performance evidence.

Food-effect considerations

The reference label reports reduced absorption with food.[1] This limits the commercial value of excipients that materially alter gastrointestinal transit, wetting, or release. A generic formulation should target dissolution behavior that is sufficiently comparable to the reference product under the applicable FDA bioequivalence conditions.

What excipients are most commercially useful in sotalol tablets?

Fillers and compression aids

Microcrystalline cellulose is commercially attractive because it supports direct compression, robust tablet hardness, and broad supplier availability. Lactose monohydrate can reduce cost and improve tablet mass, but its use requires assessment of lactose sensitivity, moisture behavior, and compatibility with the selected manufacturing process.

Dicalcium phosphate is another possible filler, although its density and compression behavior may be less attractive for a compact tablet platform. Mannitol can provide a more premium mouthfeel in chewable or orally disintegrating concepts, but its cost and potential cooling sensation may not justify use in a conventional swallowed tablet.

Disintegrants

Crospovidone, croscarmellose sodium, and sodium starch glycolate are standard options. Crospovidone is attractive for rapid water uptake and low gelling tendency. Croscarmellose sodium can provide strong wicking performance, while sodium starch glycolate may be cost-effective but requires careful control of concentration and compression force.

For sotalol, the development target should be rapid, consistent disintegration without creating excessive friability or tablet expansion.

Lubricants and flow aids

Magnesium stearate remains the dominant lubricant. Its concentration and blending time should be minimized to avoid hydrophobic over-lubrication. Colloidal silicon dioxide can improve powder flow, especially where the formulation contains a high proportion of fine active or low-dose blend components.

Alternative lubricants such as sodium stearyl fumarate may offer a route to improved dissolution robustness, but any change must be evaluated against cost, supplier qualification, and bioequivalence requirements.

What formulation patents protect sotalol hydrochloride products?

Sotalol hydrochloride is an old small-molecule product with extensive generic competition. The primary immediate-release tablet concept is not generally protected by a commercially significant composition-of-matter patent estate.

IP category	Commercial assessment
Active-ingredient patent	Historical rights are expired or commercially immaterial
Conventional tablet formulation	Low barrier; multiple excipient systems can be developed
Oral solution	Potentially protectable through formulation, stability, flavor, packaging, or use claims
Method-of-use claims	Possible around patient populations or dosing regimens, but clinical and enforceability value varies
Manufacturing process	May protect a specific process, impurity-control method, or solid-state attribute
Device and packaging	Possible protection for dosing syringes, unit-dose systems, or adherence packaging
Biosimilar protection	Not applicable; sotalol hydrochloride is a synthetic small molecule

The practical protection opportunity is therefore not a basic tablet patent. It is a narrow product platform that solves a formulation or administration problem and produces measurable regulatory or commercial differentiation.

A company evaluating freedom to operate should review current USPTO records, FDA Orange Book listings, FDA-approved labels, and jurisdiction-specific patent databases. Historical patents may remain relevant to ownership or prosecution history even where they no longer block launch.[6,7]

What is the Orange Book status of sotalol hydrochloride?

Sotalol hydrochloride is regulated as a small-molecule drug through the abbreviated new drug application pathway for generic products. The Orange Book identifies reference-listed drugs and approved generic equivalents, but it does not create a continuing exclusivity barrier for a mature product solely because the reference brand remains listed.[6]

The key regulatory distinction is between:

• A reference product with no meaningful unexpired patent or exclusivity barrier.
• A generic product that must still demonstrate pharmaceutical equivalence and bioequivalence.
• A differentiated formulation requiring its own 505(b)(2) or new-drug strategy.

The absence of a major blocking patent does not eliminate development risk. Sotalol products must meet manufacturing, impurity, dissolution, stability, labeling, and pharmacovigilance requirements. The cardiac safety profile also increases the consequences of dose or content-uniformity failures.

When does sotalol hydrochloride lose exclusivity?

The core sotalol hydrochloride tablet market has already passed the primary small-molecule exclusivity period. The commercial market is therefore driven by generic pricing, supply reliability, product availability, and dosage-form differentiation rather than by reference-product exclusivity.

Paragraph IV challenges

Paragraph IV certification can still arise where an applicant references a listed patent for a specific product, formulation, method of use, or delivery system. For conventional sotalol hydrochloride tablets, the relevant commercial question is whether an unexpired patent is listed against the targeted reference product at the time of filing.

A generic applicant can enter through:

• Paragraph III certification if a listed patent remains in force.
• Paragraph IV certification if the applicant challenges validity, enforceability, or infringement.
• A section viii statement that omits a patented method of use.
• A 505(b)(2) application for a materially different formulation or administration route.

For a mature immediate-release tablet, paragraph IV litigation is less likely to create durable market protection than in newer products. The greater risk is supply disruption caused by manufacturing observations, recalls, or limited supplier capacity.

What oral-solution opportunities exist for sotalol hydrochloride?

The oral solution is the highest-value excipient opportunity because it addresses administration barriers that tablets cannot solve.

Pediatric dosing

Pediatric use requires accurate measurement at individualized doses. A 5 mg/mL concentration allows dose calculations in 0.1 mL increments, subject to the prescribed dose and device accuracy. The product must support oral syringes that minimize residual volume and measurement error.

Sotalol oral solution has been associated with pediatric dosing considerations and must be used within the approved labeling framework. A manufacturer should not assume that a liquid automatically creates pediatric market access; clinical labeling, dosing instructions, device validation, and stability data remain important.[8]

Taste masking

Sotalol hydrochloride can produce a bitter or medicinal taste. A successful taste-masking system should not materially alter dose delivery, chemical stability, or absorption.

Potential tools include:

• Sucralose or other high-intensity sweeteners.
• Fruit or citrus flavor systems.
• Buffer optimization.
• Ion-pairing or resin-complex approaches.
• Polymer-based taste barriers.
• A low-viscosity suspension or emulsion system where justified.

A simple sweetener-and-flavor system is likely to have the lowest development and regulatory burden. Ion-exchange resin complexes may provide stronger taste control but add complexity, possible dose-release concerns, and additional raw-material qualification.

Preservation and packaging

An aqueous multidose product needs microbiological control throughout its in-use period. Candidate preservatives may include methylparaben, propylparaben, or alternative systems, subject to pH, packaging, and preservative-effectiveness testing.

Single-dose packaging can reduce preservative requirements and improve institutional handling, but it increases packaging cost and logistics complexity. Unit-dose cups, stick packs, and prefilled oral syringes are possible commercial extensions.

How strong is the sotalol hydrochloride patent estate?

The patent estate is weak for standard tablets and potentially moderate for a narrow liquid, device, or manufacturing innovation.

Asset type	Patent strength	Likely commercial value
Standard immediate-release tablet	Low	Cost and supply competition
5 mg/mL oral solution	Low to moderate	Patient access and dosing convenience
Taste-masked liquid	Moderate if technically distinct	Pediatric and dysphagia positioning
Prefilled dosing device	Moderate	Convenience, accuracy, adherence
Stability-enhanced formulation	Moderate	Longer shelf life or reduced storage burden
New indication	Variable	Requires clinical and regulatory support
Manufacturing impurity-control process	Moderate	CMC differentiation and supply resilience

A patent claiming only a routine combination of standard excipients would face validity and obviousness pressure. Stronger claims would tie the excipient system to a defined technical result, such as a specified stability profile, taste threshold, dosing accuracy, dissolution profile, or impurity limit.

What manufacturing and IP barriers affect sotalol hydrochloride?

Manufacturing barriers are more important than active-ingredient patent barriers.

Chemical and analytical controls

The development program should control:

• Assay and content uniformity.
• Related substances and degradation products.
• Water content.
• Tablet hardness and friability.
• Disintegration and dissolution.
• Solution pH and appearance.
• Preservative content.
• Microbial limits.
• Extractables and leachables for liquid packaging.

Sotalol’s renal elimination and narrow cardiac safety margin increase the importance of consistent dose delivery. The product does not require a complex drug-delivery system, but it does require strong analytical control.

Supply-chain barriers

Commercial risk can arise from dependence on a single source of:

• Sotalol hydrochloride active pharmaceutical ingredient.
• Pharmaceutical-grade lactose or cellulose.
• Flavor and sweetener systems.
• Preservatives.
• Oral syringes or dosing cups.
• High-barrier bottles and closures.

A dual-source excipient strategy can reduce shortage exposure. The best candidates are interchangeable excipients that do not change dissolution, viscosity, pH, preservative performance, or bioequivalence.

Which companies are challenging sotalol hydrochloride?

Sotalol hydrochloride is already challenged by a broad generic field rather than by one identified late-stage challenger. Generic manufacturers and marketers have historically included major and specialty suppliers such as Teva, Upsher-Smith, Mylan/Viatris, Zydus, Cipla, and other ANDA holders, depending on dosage form, strength, and market period.[6,9]

Competition should be assessed at the product-NDC and dosage-form level. A company may have approval but limited commercial supply, while another may have a narrow distribution footprint or only selected strengths. The relevant competitive variables are:

• Number of active manufacturers.
• Current wholesaler availability.
• Dosage-form coverage.
• Strength coverage.
• Tablet versus oral-solution availability.
• Institutional contract position.
• FDA inspection and shortage history.
• Ability to supply all renal-dose regimens.

What generic launch risks exist for sotalol hydrochloride?

A conventional tablet launch faces low patent risk but meaningful operational risk.

Launch scenario	Probability profile	Commercial consequence
Low-cost tablet entry	High feasibility	Rapid price erosion
New oral solution	Moderate feasibility	Higher differentiation and lower direct competition
Taste-masked pediatric liquid	Moderate feasibility	Potential premium, but limited patient population
Prefilled oral syringe	Moderate feasibility	Device and packaging value
Modified-release formulation	Low commercial rationale	Higher clinical and regulatory burden
Compounded-liquid replacement	Moderate opportunity	Requires stability and regulatory positioning

The most defensible launch strategy is a differentiated oral solution supported by validated dosing devices, reliable stability, and a clear patient-access proposition. A tablet-only strategy is more exposed to price compression unless it offers supply reliability or a lower-cost manufacturing model.

How does sotalol hydrochloride compare with competing antiarrhythmics?

Sotalol competes with amiodarone, dofetilide, dronedarone, flecainide, propafenone, and beta-blocker-based approaches, depending on indication and patient characteristics. Its formulation opportunity is distinctive because the drug is already highly soluble and available in inexpensive tablet form.

Drug	Formulation opportunity	Main commercial constraint
Sotalol hydrochloride	Oral solution, taste masking, dosing devices	QT prolongation and renal dosing
Amiodarone	Tablets, liquids, injectable products	Complex safety profile and formulation history
Dofetilide	Capsules	Dose initiation and QT monitoring
Dronedarone	Tablets	Branded pricing and clinical positioning
Flecainide	Tablets, oral solution in some markets	Narrow therapeutic use and generic competition
Propafenone	Tablets, extended-release capsules	Release technology and drug interactions

Sotalol’s strongest product-development angle is administration flexibility, not improved solubility or extended release.

What licensing deals and commercial partnerships are relevant?

The commercial licensing opportunity is more likely to involve a product platform than the sotalol molecule itself. Potential deal structures include:

• Licensing a ready-to-file oral-solution formulation.
• Acquiring a taste-masking technology for pediatric medicines.
• Contract manufacturing of 5 mg/mL solution.
• Co-development of prefilled oral syringes.
• Regional commercialization rights for hospital and specialty-pharmacy channels.
• Supply agreements for qualified excipients and packaging components.

A licensee should value regulatory readiness, demonstrated stability, device compatibility, and manufacturing scale more heavily than broad composition claims. A routine tablet formulation is unlikely to support a substantial royalty position.

What is the FDA regulatory status of sotalol hydrochloride?

FDA-approved sotalol products are available as immediate-release tablets, and sotalol hydrochloride oral solution has also received FDA approval.[1,8] Generic tablets generally proceed through ANDA applications. A materially differentiated liquid, device combination, or new clinical use may require a 505(b)(2) pathway depending on the proposed product and reliance strategy.

The main regulatory workstreams are:

• Pharmaceutical equivalence.
• Bioequivalence.
• Comparative dissolution.
• Stability and container-closure performance.
• Preservative effectiveness for multidose liquids.
• Dosing-device accuracy.
• Pediatric or geriatric usability.
• Renal-dose instructions.
• QT-related labeling consistency.

Key Takeaways

• Standard sotalol hydrochloride tablets have low patent barriers and high price competition.
• The most attractive excipient opportunity is a stable, palatable 5 mg/mL oral solution.
• Taste masking, preservative selection, buffer design, and dosing-device accuracy are the main liquid-development variables.
• Solubility-enhancing technologies are unlikely to create sufficient value for a highly soluble active ingredient.
• Renal elimination and QT-prolongation risk make dose uniformity and dosing accuracy commercially important.
• A defensible patent strategy should focus on defined formulation performance, packaging, device integration, stability, or manufacturing controls.
• Generic launch risk is driven more by price erosion, supply reliability, and regulatory execution than by an active patent estate.
• The best licensing assets are ready-to-file liquid platforms and validated delivery systems.

FAQs About Sotalol Hydrochloride Excipients and Commercial Strategy

Can sotalol hydrochloride be formulated as a liquid without a complex solubilizer?

Yes. The hydrochloride salt is highly water-soluble, so a conventional aqueous solution may be feasible. The critical issues are taste, pH, chemical stability, microbial control, and packaging compatibility.

What is the best sweetener for sotalol hydrochloride oral solution?

Sucralose is a practical candidate because it provides high sweetness at low concentration and has broad pharmaceutical use. Final selection depends on taste testing, pH stability, preservative compatibility, and regulatory acceptability.

Is sotalol hydrochloride suitable for an orally disintegrating tablet?

Technically, it may be suitable because of its solubility and relatively straightforward dose strengths. Commercial value is uncertain because an orally disintegrating tablet would need to offer meaningful administration benefits over a conventional tablet or oral solution.

Can an excipient patent protect a generic sotalol product?

It can protect a genuinely differentiated formulation, but a claim limited to routine excipient selection is vulnerable to obviousness challenges. Stronger protection requires a specific composition linked to measurable performance or stability results.

Does sotalol hydrochloride have biosimilar competition?

No. Sotalol hydrochloride is a synthetic small-molecule drug. Competition proceeds through generic-drug pathways, primarily ANDAs, rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). Betapace and Betapace AF prescribing information.
2. DailyMed. (2024). Sotalol hydrochloride tablet drug label. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. United States Pharmacopeia. (2024). Sotalol hydrochloride monograph.
5. DailyMed. (2024). Sotalol hydrochloride tablets, inactive ingredients and product labeling. National Library of Medicine.
6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
7. United States Patent and Trademark Office. (2024). Patent Center.
8. U.S. Food and Drug Administration. (2023). Sotylize prescribing information.
9. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.